Five-year survival and costs of care in metastatic colorectal cancer : conventional versus monoclonal antibody-based treatment protocols
(2015) In Expert Review of Anticancer Therapy 15(8). p.70-963- Abstract
AIM: To evaluate the costs and survival estimates of metastatic colorectal carcinoma patients treated with conventional cytostatic protocols and adjuvant monoclonal antibodies (mAbs).
METHODS: Retrospective randomized case series and cost-of-illness analysis was used. Metastatic colorectal carcinoma cases (62) were randomly selected from the archive of the largest university military hospital in Southeastern Europe.
RESULTS: A 6-month longer survival was attributed to mAbs (p = 0.581). Conventional protocols incurred € 5137 (95% CI: € 3758-€ 6517) versus € 22,113 (95% CI: € 16,201-€ 28,025) total direct medical costs in mAb-based group. ICER of € 32,108 per life year gained attributable to mAbs three-fold exceeded informal... (More)
AIM: To evaluate the costs and survival estimates of metastatic colorectal carcinoma patients treated with conventional cytostatic protocols and adjuvant monoclonal antibodies (mAbs).
METHODS: Retrospective randomized case series and cost-of-illness analysis was used. Metastatic colorectal carcinoma cases (62) were randomly selected from the archive of the largest university military hospital in Southeastern Europe.
RESULTS: A 6-month longer survival was attributed to mAbs (p = 0.581). Conventional protocols incurred € 5137 (95% CI: € 3758-€ 6517) versus € 22,113 (95% CI: € 16,201-€ 28,025) total direct medical costs in mAb-based group. ICER of € 32,108 per life year gained attributable to mAbs three-fold exceeded informal willingness to pay threshold of Serbia.
CONCLUSION: mAbs adjuvant protocols had modest positive impact on 5-year survival rates. Costs were driven by targeted biologicals, but significantly higher costs of care were recorded in mAb-treated group in other domains, as well. More selective prescription and reimbursement criteria should be applied to increase cost-effectiveness of targeted oncology agents.
(Less)
- author
- Kovacevic, Aleksandra ; Dragojevic-Simic, Viktorija ; Tarabar, Dino ; Rancic, Nemanja ; Jacimovic, Nemanja ; Katic, Jelena ; Dagovic, Aleksandar and Jakovljevic, Mihajlo LU
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- keywords
- Aged, Antibodies, Monoclonal/economics, Antineoplastic Combined Chemotherapy Protocols/economics, Colorectal Neoplasms/drug therapy, Cost-Benefit Analysis, Female, Hospitals, Military, Hospitals, University, Humans, Male, Middle Aged, Neoplasm Metastasis, Randomized Controlled Trials as Topic, Retrospective Studies, Serbia, Survival Rate
- in
- Expert Review of Anticancer Therapy
- volume
- 15
- issue
- 8
- pages
- 70 - 963
- publisher
- Future Drugs Ltd
- external identifiers
-
- pmid:26089093
- scopus:84937834032
- ISSN
- 1744-8328
- DOI
- 10.1586/14737140.2015.1059280
- language
- English
- LU publication?
- no
- id
- a2466101-feac-41b1-9ab8-e6b55705da3f
- date added to LUP
- 2018-09-01 22:53:25
- date last changed
- 2024-04-15 10:52:10
@article{a2466101-feac-41b1-9ab8-e6b55705da3f,
abstract = {{<p>AIM: To evaluate the costs and survival estimates of metastatic colorectal carcinoma patients treated with conventional cytostatic protocols and adjuvant monoclonal antibodies (mAbs).</p><p>METHODS: Retrospective randomized case series and cost-of-illness analysis was used. Metastatic colorectal carcinoma cases (62) were randomly selected from the archive of the largest university military hospital in Southeastern Europe.</p><p>RESULTS: A 6-month longer survival was attributed to mAbs (p = 0.581). Conventional protocols incurred € 5137 (95% CI: € 3758-€ 6517) versus € 22,113 (95% CI: € 16,201-€ 28,025) total direct medical costs in mAb-based group. ICER of € 32,108 per life year gained attributable to mAbs three-fold exceeded informal willingness to pay threshold of Serbia.</p><p>CONCLUSION: mAbs adjuvant protocols had modest positive impact on 5-year survival rates. Costs were driven by targeted biologicals, but significantly higher costs of care were recorded in mAb-treated group in other domains, as well. More selective prescription and reimbursement criteria should be applied to increase cost-effectiveness of targeted oncology agents.</p>}},
author = {{Kovacevic, Aleksandra and Dragojevic-Simic, Viktorija and Tarabar, Dino and Rancic, Nemanja and Jacimovic, Nemanja and Katic, Jelena and Dagovic, Aleksandar and Jakovljevic, Mihajlo}},
issn = {{1744-8328}},
keywords = {{Aged; Antibodies, Monoclonal/economics; Antineoplastic Combined Chemotherapy Protocols/economics; Colorectal Neoplasms/drug therapy; Cost-Benefit Analysis; Female; Hospitals, Military; Hospitals, University; Humans; Male; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Retrospective Studies; Serbia; Survival Rate}},
language = {{eng}},
number = {{8}},
pages = {{70--963}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Anticancer Therapy}},
title = {{Five-year survival and costs of care in metastatic colorectal cancer : conventional versus monoclonal antibody-based treatment protocols}},
url = {{http://dx.doi.org/10.1586/14737140.2015.1059280}},
doi = {{10.1586/14737140.2015.1059280}},
volume = {{15}},
year = {{2015}},
}